Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited has received approval from China’s National Medical Products Administration for a supplementary drug application related to the marketing authorization transfer of esmolol hydrochloride injection. This approval marks a significant step for the company, following a technology transfer agreement with Beijing Minkang Baicao Pharmaceutical Technology. Investors may find this development noteworthy as it strengthens Xinhua Pharmaceutical’s position in the pharmaceutical market.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.